HC Wainwright reiterated their buy rating on shares of Redhill Biopharma Ltd. (NASDAQ:RDHL) in a research note released on Tuesday morning. HC Wainwright currently has a $36.00 price objective on the biotechnology company’s stock.

A number of other equities research analysts have also recently weighed in on the stock. Zacks Investment Research upgraded shares of Redhill Biopharma from a hold rating to a buy rating and set a $5.50 price target for the company in a research report on Friday, November 17th. Roth Capital dropped their price target on shares of Redhill Biopharma from $27.00 to $20.00 and set a buy rating for the company in a research report on Tuesday, November 14th. Seaport Global Securities assumed coverage on shares of Redhill Biopharma in a research report on Friday, October 6th. They set a buy rating and a $19.00 price target for the company. Finally, UBS AG assumed coverage on shares of Redhill Biopharma in a report on Wednesday, September 13th. They issued a reduce rating for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $21.10.

Shares of Redhill Biopharma (NASDAQ:RDHL) opened at $5.09 on Tuesday. Redhill Biopharma has a 12-month low of $4.82 and a 12-month high of $12.09.

COPYRIGHT VIOLATION NOTICE: “Redhill Biopharma’s (RDHL) “Buy” Rating Reiterated at HC Wainwright” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/redhill-biopharmas-rdhl-buy-rating-reiterated-at-hc-wainwright/1723647.html.

Several hedge funds have recently made changes to their positions in RDHL. Renaissance Technologies LLC grew its holdings in shares of Redhill Biopharma by 144.1% in the first quarter. Renaissance Technologies LLC now owns 62,000 shares of the biotechnology company’s stock valued at $595,000 after purchasing an additional 36,600 shares in the last quarter. Family Management Corp grew its holdings in shares of Redhill Biopharma by 46.6% in the third quarter. Family Management Corp now owns 37,750 shares of the biotechnology company’s stock valued at $408,000 after purchasing an additional 12,000 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Redhill Biopharma in the first quarter valued at approximately $101,000. D.A. Davidson & CO. grew its holdings in shares of Redhill Biopharma by 10.0% in the second quarter. D.A. Davidson & CO. now owns 44,000 shares of the biotechnology company’s stock valued at $379,000 after purchasing an additional 4,000 shares in the last quarter. Finally, Oppenheimer & Co. Inc. grew its holdings in shares of Redhill Biopharma by 10.8% in the second quarter. Oppenheimer & Co. Inc. now owns 25,569 shares of the biotechnology company’s stock valued at $220,000 after purchasing an additional 2,500 shares in the last quarter. Hedge funds and other institutional investors own 10.63% of the company’s stock.

Redhill Biopharma Company Profile

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.